What one share of Polaryx Therapeutics holds
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need.
Polaryx Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.15 |
|---|---|
| Cash and investments | $0.23 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.89 | — | — | — | $0.11 |
| 2025 | — | −$0.20 | — | — | — | $0.10 |
Common questions about Polaryx Therapeutics
How much does one share of Polaryx Therapeutics earn?
Over the last 12 months, Polaryx Therapeutics lost $0.15 for each share.
Does Polaryx Therapeutics pay a dividend?
Polaryx Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Polaryx Therapeutics’s book value per share?
Polaryx Therapeutics’s book value is $0.22 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Polaryx Therapeutics have?
Each share of Polaryx Therapeutics has $0.23 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.